New DNA vaccine aims to train immune system against lung cancer
NCT ID NCT05242965
First seen Apr 14, 2026 · Last updated Apr 24, 2026 · Updated 3 times
Summary
This study tests a DNA vaccine called STEMVAC in people with stage IV non-small cell lung cancer. The vaccine gives the body instructions to make parts of five proteins found on lung cancer cells, helping the immune system recognize and attack them. The trial includes 5 participants who are already on maintenance therapy. The goal is to see if the vaccine can shrink tumors and boost immune response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG NON-SMALL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
-
University of Nebraska Medical Center
Omaha, Nebraska, 98198, United States
Conditions
Explore the condition pages connected to this study.